SCHEMBL22079708

SCHEMBL22079708

CCOC(=O)N1CC2CCC1CC2N1CC(OC(=O)N2CCCOCC2)C1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
RECQL P46063 1/20 0.40
CHRM1 P11229 4/20 0.39
ALDH1A1 P00352 4/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
TP53 P04637 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
PKM P14618 1/20 0.33
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22032105 0.91 TP53 (0.39) TSHRCHRM1ALDH1A1L3MBTL1TP53
SCHEMBL22032121 0.90 CHRM1 (0.40) TSHRCHRM1ALDH1A1L3MBTL1TP53
SCHEMBL22032116 0.90 CHRM1 (0.40) TSHRCHRM1ALDH1A1L3MBTL1TP53
SCHEMBL24106280 0.90 CHRM1 (0.40) TSHRCHRM1ALDH1A1L3MBTL1TP53
SCHEMBL22032093 0.86 TSHR (0.40) TSHRRECQLCHRM1ALDH1A1LMNA
SCHEMBL22079709 0.81 CHRM1 (0.51) TSHRRECQLCHRM1ALDH1A1LMNA
SCHEMBL22032075 0.77 DPP4 (0.34) CHRM1TP53TDP1
SCHEMBL22032095 0.75 TP53 (0.36) CHRM1ALDH1A1TP53TDP1CYP3A4
SCHEMBL22032090 0.75 CHRM1 (0.39) TSHRCHRM1ALDH1A1POLBRAB9A
SCHEMBL24106281 0.73 TSHR (0.44) TSHRRECQLCHRM1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11945801-B2 Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2024-04-02 US claimed
US-20210387969-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2021-12-16 US disclosed
WO-2020115505-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210387969-A1 BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 AND/OR M4 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM4 TSHR 81/4885RECQL 1199/4885CHRM1 1/4885
US-11945801-B2 Bicyclic aza compounds as muscarinic M1 and/or M4 receptor agonists CHRM1, CHRM2, CHRM4 TSHR 81/4885RECQL 1199/4885CHRM1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.